Skip to main content

Tweets

MSK Syndrome from Dupilimab, an IL-4/13 Inhibitor. A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab. https://t.co/w5djtUzAGG https://t.co/eGMJQJ6Pw2
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
Prospective study.of 370 #FM pts (79% F; age 34yrs), and 79% were female w/ 14.3 tender points. A delay in Dx was signif correlated with Sx Severity Scale (r = 0.14) & tender points (r = 0.16), but not widespread pain. Early Dx = less severe FM. https://t.co/URvzRa1c3P

Dr. John Cush @RheumNow ( View Tweet )

2 years 1 month ago
Analysis of 14,958 RA pts in Japans National Database of Rheumatic Diseases (NinJa) shows women had higher DAS28-ESR values than males, despite no obvious difference in other indices or disease activity categories. https://t.co/bLFmRdulCw

Dr. John Cush @RheumNow ( View Tweet )

2 years 1 month ago
Metanalysis of Steroids in hosp community-acquired pneumonia (CAP). 18 studies, 4661 pts. Corticosteroids reduced mortality in more severe CAP(RR 0.62; 0.45 to 0.85), but not less severe CAP(RR 1.08). Steroids lower need for mech ventilation, ICU https://t.co/1QbuCZRXze https://t.co/16qiqIatJq
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/LNIqQxQFKK

Dr. John Cush @RheumNow ( View Tweet )

2 years 1 month ago
Denosumab Reduces Type II Diabetes Risk. The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/vZALPMU8lI https://t.co/yGvDLHIp5y
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
RheumNow Live is just about a month away--will we see you there? You can attend virtually or in-person at our Dallas, TX location. With over 20 dynamic speakers, we are confident you'll leave feeling inspired! https://t.co/y6BVvZDcku https://t.co/NqzkVd3l8p
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
How Being a Patient Taught Me to Be a Better Doctor” Dr. Marcella Ferrada (@maferradastrong ) shares her experience having a rare disease and how it positively impacted her skills as a physician. https://t.co/BZPlLzdSsk https://t.co/Ykh6AhAnxn
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
Browse through this update to learn more about the real impact of comorbidities on patients living with SpA. Sponsored by Novartis Medical Affairs. https://t.co/0BCVvTYzAl https://t.co/2RhJomr6Dr
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
Denosumab Reduces Type II Diabetes Risk. The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/eUu23a2QDn https://t.co/RHDLTm9NMD
Dr. John Cush @RheumNow ( View Tweet )
2 years 1 month ago
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family? Click here to answer >> https://t.co/IagcDC24rZ

Dr. John Cush @RheumNow ( View Tweet )

2 years 1 month ago
×